Summary Plasma lipoproteins, such as low-density lipoprotein (LDL), have been proposed to enhance the delivery of hydrophobic photosensitisers to malignant tissue since tumour cells have been shown to have increased numbers of LDL receptors. We have investigated the role of this receptor in the cellular accumulation of the photosensitiser benzoporphyrin derivative (BPD). We observed that: (1) [`4C]BPD-LDL accumulation by LDL receptor-negative fibroblast cell lines was insignificant compared with normal cell lines; (2) there was no evidence that BPD dissociated from LDL during incubation with the cells; and (3) chemical acetylation of LDL markedly decreased the uptake of ['4C]BPD-LDL. We conclude, therefore, that virtually all of the photosensitiser accumulated by the cells was due to specific binding and internalisation via the LDL receptor. Subsequent in vivo studies in M-1 (methylcholanthrene-induced rhabdomyosarcoma) tumour-bearing DBA/2J mice showed that tumour accumulation of BPD associated with native LDL was significantly (P<0.01) enhanced over that of acetyl-LDL-associated BPD. These results indicate that the LDL receptor is responsible for the accumulation of LDL-associated BPD both in vitro and in vivo. Thus, utilisation of this delivery system may provide for improvements in photodynamic therapy in clinical practice.
Photodynamic therapy (PDT) has been used since 1976 to treat a wide variety of malignant tumours (Manyak et al., 1988; Gomer et al., 1989; Henderson et al., 1992) . The therapy consists of the systemic administration of a photosensitiser followed by exposure of the target tissue to light of the appropriate wavelength. Light activation of the photosensitiser results in the production of reactive oxygen species that subsequently act as the cytotoxic agent (Weishaupt et al., 1976) . The advantage of PDT over conventional therapies is that it is relatively non-invasive and has limited toxicity (Dougherty et al., 1990) . Toxicity is minimised by the ability to restrict the light activation to the tumour site and increased accumulation of the photosensitiser within tumour tissue compared with unaffected tissue (Moan & Berg, 1992) . Relatively little is known about the mechanisms governing the accumulation of photosensitisers in tumours. However, plasma lipoproteins are thought to play a key role since they act as high-capacity carriers of hydrophobic photosensitisers in the blood (Barel et al., 1986; Kessel, 1986) . Many malignant tissues express an increased number of low-density lipoprotein (LDL) receptors compared with normal tissues Gal et al., 1981; Vitols et al., 1984) , suggesting that LDL should be the ideal vehicle for delivery of anti-cancer agents, including photosensitisers (Norata et al., 1984; Lundberg, 1991) .
LDL is the class of plasma lipoprotein particles which carries the majority of cholesterol and cholesteryl esters in plasma (Gotto et al., 1986) . Approximately half of plasma LDL is removed by the high-affinity LDL receptors in the liver, and the remainder gains access to extravascular compartments of other tissues and organs, where LDL receptors mediate the delivery of cholesterol to peripheral cells (Attie et al., 1982) . Thus, the distribution of LDL to extrahepatic tissues depends upon the rate of transcapillary transport and the number of LDL receptors on cell surfaces. Increases in the permeability of tumour vasculature (Paterson & Appergren, 1973 ) and the number of LDL receptors on tumour cells Gal et al., 1981; Vitols et al., 1984) strong affinity for lipoproteins when mixed with plasma in vitro or in vivo (Allison et al., 1990) . In subsequent experiments in tumour-bearing mice, administration of BPD premixed with LDL resulted in enhanced delivery to tumours and increased photosensitisation when compared with BPD administered in aqueous solution . Similar studies by other groups have demonstrated that the association of haematoporphyrin, haematoporphyrin derivative and Photofrin with LDL can lead to enhanced delivery to tumours in mice (Jori et al., 1984; Candide et al., 1986) . In light of these reports and our evidence that LDL association enhances delivery of BPD to tumour tissue, we hypothesised that receptor-mediated endocytosis of BPD-LDL complexes might be an important mechanism in the selective accumulation of this photosensitiser in tumour tissue. In the present study, we have determined the role of the LDL receptor in the binding and internalisation of BPD-LDL mixtures of fibroblasts and M-1 tumour cells in vitro. In addition, we investigated the contribution of LDL receptormediated delivery by BPD-LDL complexes to tumours in mice. The results clearly indicate that the LDL receptor is responsible for virtually all the accumulation of BPD-LDL complexes in vitro and is also a major contributor to the selective delivery of this photosensitiser to tumours in vivo.
Materials and methods

Cell lines
Human fibroblast cell lines were purchased from the Human Genetic Mutant Cell Repository (Coriell Institute for Medical Research, Camden, NJ, USA). GM3348B is a normal fibroblast cell line and GM2000E is a mutant fibroblast cell line which has no LDL receptors. The fibroblasts were grown in Dulbecco's modified Eagle medium (DMEM, Gibco, Grand Island, NY, USA) with 20% fetal calf serum (FCS). The M-1 cell line is a rhabdomyosarcoma of DBA/2J mice which has been maintained in this laboratory in vitro and in vivo for the past decade (Richter et al., 1987) . All cell lines were maintained in a humidified 5% carbon dioxide incubator.
Photosensitiser BPD was produced from haematoporphyrin via protoporphyrin as previously described (Panka et al., 1986 ) and obtained from Quadra Logic Technologies. The structure of BPD is shown in Figure 1 . One of the structural analogues of the previously described synthetic process, BPD-MA, was used exclusively in these studies and will be referred to as BPD hereafter (Richter et al., 1987) . ['4C]BPD was synthesised in the laboratory of D. Dolphin, in the Department of Chemistry, University of British Columbia . BPD concentration was measured by reading the absorbance at a wavelength of 688 nm in a solution of 50% methanol, 1% Triton X-100 in PBS. An extinction coefficient of 23,384.6 M-l cm-' was used to calculate the concentration of such BPD solutions.
Lipoprotein preparation LDL was isolated from fresh human plasma by sequential ultracentrifugation at a density of 1.019-1.063 g ml-' (Havel et al., 1955) . Following isolation, the LDL was dialysed for 24 h against two changes of a Tris-EDTA buffer (0.15 M sodium chloride, 10 mM Tris-HCl, 0.10% EDTA, 0.05% sodium azide, pH 7.4) at 4°C. The lipoprotein concentration was estimated by analysis of protein content (Lowry et al., 1961) , and the purity of each preparation was determined by agarose gel electrophoresis (Nobel, 1968) . Each LDL preparation was stored at 4°C and used within 2 weeks of isolation.
Purified LDL was iodinated using an adaptation of the iodine monchloride method described by McFarlane (1958 Acetylated LDL (Ac-LDL) was prepared by reacting the free amino groups of the lipoprotein with acetic anhydride. This process increases the net negative charge and destroys the ability of the lipoprotein particle to bind to the LDL receptor (Basu et al., 1976) . The increase in net negative charge also increases the electrophoretic mobility of the acetylated LDL; therefore, agarose gel electrophoresis (Nobel, 1968) was used to confirm that the LDL had been successfully acetylated. The trinitrobenzenesulphonic acid (TNBS) assay (Habeeb, 1966) indicated that 30% of the free amino groups in the LDL preparation had been modified.
[ 
Accumulation of ['4C]BPD-LDL or ['4C]BPD-Ac-LDL by culturedfibroblasts in vitro
Fibroblast cells (1 x 105) were seeded into 60 mm Petri dishes containing 3 ml of DME with 20% fetal calf serum (FCS) on day zero. On day 3, the medium was replaced with fresh medium containing 10% FCS. On day 5 or 6, when the cells were approximately 80% confluent, each dish was washed with 2 ml of PBS and the medium was replaced with 2 ml of DME containing 2.5 mg ml-' LPDFCS. Incubation of the cells in LPDFCS serves to increase the number of LDL receptors per cell (Goldstein et al., 1983) . The binding and uptake of the BPD-LDL mixtures was studied after the cells had been incubated for 48 h in medium with LPDFCS.
Prior to each experiment, the medium was removed from the dishes and the cells were washed once with 2 ml of PBS. The PBS was replaced with 1 ml of DME containing the appropriate concentrations of BPD and LDL or Ac-LDL and 1% LPDFCS in the presence or absence of 25-fold excess LDL or Ac-LDL. The cells were incubated in these solutions for 2 h at 37°C. The dishes of cells were then transferred to 4°C and washed three times for 2 min with 4°C PBS containing 2 mg ml1' BSA, followed by two 2 min incubations in 4°C PBS. The cells were then dissolved by exposure to 1 ml of 0. At 3 h post injection, mice were sacrificed by cervical dislocation under halothane anaesthesia and samples of blood, liver and tumour tissue were removed. Samples were placed in 7 ml vials, minced and the wet weight or volume was determined. The amount of BPD recovered in each tissue was determined as previously described ).
Results
Accumulation of ['4C]BPD-LDL by culturedfibroblasts
The kinetics of LDL binding and internalisation by the cell lines used was confirmed by preliminary ['25I ]LDL uptake studies. The measured ['25I1LDL binding to the normal fibroblasts (GM3348B) was similar to the LDL binding curves published by (Goldstein et al. (1974) , whereas no specific binding of ['25I ]LDL occurred with the receptornegative cells.
The ability of these fibroblasts to accumulate BPD-LDL was studied at several concentrations of ['4C]BPD which had been pre-equilibrated with 10l gml-' LDL. At this concentration, non-specific binding of LDL is usually less than 5-10% of the total binding in the normal cell line (Goldstein et al., 1983) , thus differences in the uptake by the two cell lines probably reflect differences in the activity of the LDL receptor. Figure LDL (g ml -)
Figure Figure 3 shows that this was indeed the case. By contrast, if BPD was transferred from the LDL to the plasma membrane of the cells by non-specific processes, the predicted uptake of LDL determined from the ['4C]BPD-LDL uptake study would be greater than that measured by the uptake of BPD-['25I]LDL. Thus, the data in Figure 3 add further support to the hypothesis that LDLassociated BPD is delivered to cells through the LDL receptor pathway. As the concentration of LDL was increased from 10 to 50 jig ml-', we observed a slight increase in the calculated association of LDL in the presence of the ['4C]BPD-LDL, however these differences were not significant. [
'4C]BPD-LDL accumulation by cultured M-J tumour cells
All of the experiments with the fibroblasts described above consistently showed that the LDL receptor was responsible for virtually all of the accumulation of BPD-LDL observed. To determine whether this also occurred in cell types which would be treated by PDT, the accumulation of [14CJBPD-LDL was also measured in M-1 tumour cells in vitro. In Figure 5 , (Table I) , Candide et al. (1980) showed that Photofrin II was taken up by cultured human fibroblasts more efficiently when mixed with LDL than with HDL or albumin. However, the LDL-Photofrin II uptake was greater than expected when the cells were grown in lipoproteincontaining medium. Under these conditions the cellular LDL receptor expression should be low. These investigators concluded that a non-specific LDL-Photofrin II uptake was involved in addition to the LDL receptor-mediated pathway. They later proposed that non-specific exchange of porphyrins between LDL and the plasma membrane occurs (Maziere et al., 1990 (Jori, 1989; Kongshaug et al., 1989) . Thus, the nature of the association of BPD and Photofrin II with LDL may differ, especially since Photofrin II consists of an aggregated mixture of compounds (Dougherty et al., 1987; Kessel et al., 1987) , most of which are not highly hydrophobic. Differences in photosensitisers, such as this, may be partially responsible for the conflicting LDL delivery results which had been previously reported (Korbelik et al., 1990) .
In vivo studies have demonstrated that the association of several different photosensitisers with LDL can enhance their delivery to malignant tissues (Jori et al., 1984; Zhou et al., 1988; Maziere et al., 1991) . Results of in vivo studies on the distribution, elimination and cytotoxic effects of photosensitisers in experimental tumours have been explained by eluding to the mechanism of LDL receptor-mediated endocytosis of photosensitisers, without experimental confirmation of the process (Kessel, 1986; Maziere et al., 1990; Allison et al., 1991; Richter et al., 1991) . Our in vivo studies have extended the observations of LDL receptormediated accumulation of BPD in vitro to a credible mechanism for the delivery of BPD to tumour tissue in vivo.
We compared the ability of native LDL and acetylated LDL to deliver BPD to M-1 tumours in vivo. Modification of 15% of the peptidyl lysines of LDL abrogates binding to the LDL receptor Haberland et al., 1984; Via et al., 1992) but acetylation of >29% is necessary for recognition of Ac-LDL by the scavenger receptor which recognises modified LDL Via et al., 1992) . This receptor is active on macrophage and endothelial cells, both of which might also be involved in BPD accumulation in the M-1 tumour. The inability of Ac-LDL to deliver BPD to the fibroblasts in our in vitro experiments suggests that the acetylated LDL used was no longer binding to the LDL receptor. Normally, recognition of Ac-LDL by the scavenger receptor leads to very rapid clearance from the blood via the Kupffer cells of the liver Van Berkel et al., 1991) . The markedly higher accumulation of ['4C]BPD-LDL in the liver and the similar blood levels of ["4C]BPD-LDL and ["4C]BPD-Ac-LDL observed 3 h post administration in vivo suggest that our Ac-LDL preparations were not recognised by the scavenger receptor. The TNBS assay performed on the acetylated LDL indicated that 30% of the lysines were modified, which might not have been sufficient for recognition by the scavenger receptor. Thus, the difference observed in the tumour accumulation of the two different BPD-LDL preparations was probably due exclusively to LDL receptor-mediated accumulation of the native LDL-associated BPD.
Our previous studies have suggested that the association of BPD with LDL increases access of the photosensitiser to the tumour cells within the tumour tissue . Similarly, Zhou et al. (1988) The different experimental strategies described in this paper consistently show that the LDL receptor is responsible for virtually all of the accumulation of LDL-associated BPD in vitro. Extension of these studies to tumour-bearing mice indicates that LDL receptor-mediated endocytosis also makes a major contribution to the delivery of this photosensitiser in vivo. Taken together, these studies suggest that LDL receptor-mediated endocytosis contributes substantially to the selective accumulation of BPD (and possibly other hydro-phobic photosensitisers) into malignant tissues. Characterisation and utilisation of this delivery system may provide for an improvement in PDT in clinical practice.
